Timeline
Poolbeg Pharma
Poolbeg Pharma raises £3.5m as executive chair backs placing
Shore Capital flags TOPICAL trial start as key catalyst for Poolbeg
Poolbeg doses first patient in POLB 001 TOPICAL trial
Poolbeg Pharma wins South Africa patent for POLB 001 to 2038
Poolbeg Pharma granted European patent for POLB 001 in CRS
Poolbeg activates first site for POLB 001 TOPICAL trial
Poolbeg presents POLB 001 preclinical data showing CRS reduction and potential AML benefit
Poolbeg to present POLB 001 CRS data at EHA
Poolbeg Pharma wins Canadian patent for POLB 001 CRS use
Poolbeg Pharma says TOPICAL trial gets greenlight
More in Biotech
GENinCode genetic test cuts cardiac risk in Catalonia pilot
A real-world pilot by Catalonia's health service found GENinCode's CARDIO inCode-Score reclassified risk in over 40% of moderate-risk patients and drove measurable improvements in cholesterol and smoking cessation.